New drug shows promise for rare Skin-Hardening disease
NCT ID NCT05198557
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This phase 3 study tests whether the drug MT-0551 can reduce skin thickening in people with systemic sclerosis, a rare autoimmune disease that causes hardening of the skin and internal organs. About 80 adults with moderate skin involvement will receive either MT-0551 or a placebo for 26 weeks. Researchers will measure changes in skin thickness and monitor lung function and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, 216-8511, Japan
-
The University of Tokyo Hospital
Bunkyo-ku, Tokyo, 113-8655, Japan
-
University of Fukui Hospital
Yoshida-gun, Fukui, 910-1193, Japan
Conditions
Explore the condition pages connected to this study.